Aleglitazar
Aleglitazar Uses, Dosage, Side Effects, Food Interaction and all others data.
Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity.
| Trade Name | Aleglitazar |
| Generic | Aleglitazar |
| Aleglitazar Other Names | Aleglitazar |
| Type | |
| Formula | C24H23NO5S |
| Weight | Average: 437.508 Monoisotopic: 437.129693541 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity.
How Aleglitazar works
Aleglitazar was rationally designed to be an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. Agonistic action at PPARα controls lipid levels, which improves dyslipidemia, and agonistic action at PPARγ controls glucose levels, which improves insulin sensitivity in diabetes.
Innovators Monograph
You find simplified version here Aleglitazar
